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Abstract  
Introduction: This study aims to determine the Acinetobacter sp clinical isolates frequency and its antibiotic susceptibility pattern by comparing 
results obtained from the Intensive Care Units (ICUs) to that of other units at the Mohammed V Military Teaching Hospital in Rabat. 
Methods: This is a retrospective study over a 2-years period where we collected all clinical isolates of Acinetobacter sp obtained from samples for 
infection diagnosis performed on hospitalized patients between 2012 to 2014. Results: During the study period, 441 clinical and non-repetitive 
isolates of Acinetobacter sp were collected representing 6.94% of all bacterial clinical isolates (n=6352) and 9.6% of Gram negative rods 
(n=4569). More than a half of the isolates were from the ICUs and were obtained from 293 infected patients of which 65, 2% (191 cases) were 
males (sex ratio = 1.9) and the median age was 56 years (interquartile range: 42-68 years). Acinetobacter clinical isolates were obtained from 
respiratory samples (44.67%) followed by blood cultures (14.51%). The resistance to ciprofloxacin, ceftazidime, piperacillin / tazobactam, 
imipenem, amikacin, tobramycin, netilmicin, rifampicin and colistin was respectively 87%, 86%, 79%, 76%; 52%, 43%, 33% 32% and 1.7%. The 
difference in resistance between the ICUs and the other units was statistically significant (p <0.05) except for colistin, tetracycline and rifampicin. 
 Conclusion: This paper shows that solving the problem of prevalence and high rate of multidrug resistant Acinetobacter infection which 
represents a therapeutic impasse, requires the control of the hospital environment and optimizing hands hygiene and antibiotics use in the 
hospital. 
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Introduction 
 
Acinetobacter is a non-fermenting Gram negative coccobacillus with 
a high capacity to colonize the human body and the environmental 
reservoirs [1]. It has become over the past three decades a major 
associated care infections agent with a high morbidity and a high 
mortality rate especially in immunocompromised patients ranging 
from 26.5 to 91% [2-5]. In Morocco, a retrospective study [6] from 
2002 to 2005 showed that this bacterium represented 13.63% of 
clinical isolates from blood cultures in the intensive care units (ICUs) 
[6] and in another Moroccan study [7], it represented 6.74% of all 
Gram-negative bacilli. The Acinetobacter infection prevalence is 
variable depending on the geographical localization and the patient’s 
socio-economic status [8-10]. In an international study in ICUs, 
the Acinetobacter infections rate was 19.2% in Asia; 17.1% in 
Eastern Europe; 14.8% in Africa; 13.8% in Central and South 
America; 5.6% in Western Europe; 4.4% in Oceania and 3.7% in 
North America [10]. It is 15% in South African HIV-positive patients 
[8] and 13% in Canadian burn care units [9]. In our region, no 
studies on Acinetobacter prevalence have been 
performed. Acinetobacter is an opportunistic pathogen known for its 
intrinsic resistance to antibiotics and greater ability to rapidly 
acquire resistance genes as mobile genetic elements (plasmids, 
transposons, integrons cassettes and insertion sequences) [11-13]. 
Multidrug resistant (MDR) Acinetobacter baumannii is becoming a 
global threat with a therapeutic impasse increasingly described in 
literature [14-16]. Indeed this organism generally has resistance to 
several antibiotics. According to the literature data, the resistance 
rate varies from 31.8 to 92.1% to ceftazidime; 8.8 to 89.9% vs 
imipenem, from 12.2 to 89.9% vs Piperacillin / Tazobactam, from 
28.8 to 91.6% vs fluoroquinolones and 30 to 90.3% vs 
aminoglycosides [8,17-20] but colistin is often the only effective 
treatment option whereas some Acinetobacter strains develop 
resistance to colistin [8,18-21]. Resistance to colistin was estimated 
to 5.3% in the United States [21]; 2.7% in South Africa [8]; 1.2% in 
India [20] and 0.9% in Tunisia [19] and 0.5% in Saudi Arabia [18]. 
In Morocco, the Acinetobacter’s antibiotic resistance rates were of 
50.3 to 68.7% for ceftazidime, 23.8 to 42.6% for the imipenem, 17 
to 77.5% for aminoglycosides, 65 to 68% for ciprofloxacin and no 
clinical isolates were resistant to colistin [6, 7, 22] however these 
data were inadequate and old. The purpose of this study was to 
accurately determine the prevalence rate of infections and antibiotic 
resistance level in clinical isolates of Acinetobacter by comparing 
data from the intensive care units versus other units of the 







This study was conducted in HMIMV, a teaching hospital with 700-
bed located in Rabat, Kingdom of Morocco. The hospital has 
different departments mainly 2 intensive care units (medical and 
surgical) with 10 beds each, a center for burns treatment, surgical 
and medical units, as well as laboratory and imagery departments. 
 
Type of studies 
 
This retrospective study was conducted by the laboratory of medical 
microbiology over a 2-years period. Clinical isolates were collected 
from diagnosis samples performed on patients who were 
hospitalized in different units of the HMIMV from April, 1st, 2012 to 
April, 1stst, 2014. 
 
Isolation cultures and antibiotic susceptibility 
 
Isolation of Acinetobacter was performed on blood agar and bromo-
cresol purple lactose agar and identification of clinical isolates was 
performed by classical bacteriological techniques (direct 
examination, biochemical test of orientation) and biochemical 
characters using API20NE galleries (Biomérieux, Marcy l’Etoile, 
France). The study of antibiotic susceptibility was performed by the 
disc diffusion method on Mueller-Hinton agar plates, and interpreted 
as recommended by the antibiogram committee of the French 
Society of Microbiology in their 2014 recommendations .The 
antibiotic discs tested were: ticarcillin, ticarcillin-clavulanate , 
piperacillin, piperacillin-tazobactam, cefepime, ceftazidime, 
imipenem, amikacin, gentamicin, tobramycin, netilmicin, 
ciprofloxacin, sulfamethoxazole -trimethoprime and colistin. The 
reading of the antibiograms was performed using the OSIRIS expert 
system. The resistance to colistin was confirmed by the 
determination of the Minimum Inhibitory Concentrations (MICs) 
using the E-test method (Biomérieux, Marcy l’Etoile, France) 
according to the manufacturer´s recommendations. All isolates 
of Acinetobacter resistant to three or more classes of antibiotics 
represented by piperacillin / tazobactam, ceftazidime, imipenem, 
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ciprofloxacin, aminoglycosides and colistin were considered as MDR 




The statistical analysis was performed using the SPSS Statistics 
17.0. The Chi 2 test was used to compare the percentages 
of Acinetobacter infection prevalence, resistance rates and MDR 
between ICUs and the other units. The p values less than 0.05 were 





Characteristics of Acinetobacter´s clinical isolates 
 
During the study period, 441clinical isolates of Acinetobacter were 
collected, representing 6.94% of all bacterial isolates (n=6352) and 
9.6% of all Gram-negative bacilli (n=4569) throughout the hospital. 
These isolates were obtained from 293 Acinetobacter infected 
patients of which 65.2% (191cases) were males, so a sex ratio M/F 
of 1.9. These patients represented 8, 2% of all patients having a 
bacterial infection (n=3565). The median age 
of Acinetobacter infected patients was 56 years (interquartile range: 
42-68 years) and the distribution by age showed that 64.9% of the 
isolates came from patients aged between 18-64 years; 31.3% aged 
65-101 years and 3.8% of patients ≤ 17 years. Site sampling 
analysis of the Acinetobacter’s isolates showed that the proportion 
of broncho-pulmonary samples was 44.67%, followed by the blood 
cultures (14.51%), the deep pus (12.47%), the urine (12%), the 
superficial pus (9%), the catheters (3.85%), the tissue (1.81%) and 
the puncture liquid (1.59%) (Table 1). Isolates 
of Acinetobacter under study, 358 (87.1%) were Acinetobacter 
baumannii, and 4 (1%) were Acinetobacter lwoffii. The breakdown 
by department analysis showed that 54.9% of clinical isolates were 
obtained from the ICUs, 36.7% and 8.4% from the medical and 
surgical units respectively. In the ICUs, the isolates of 
collected Acinetobacter strains (n=242) represented 24.85% of all 
isolates (n=974) and 31.5% of all Gram-negative bacilli (n=769). 
They were collected from 156 patients infected with Acinetobacter. 
For these patients 61.53% were male with a sex ratio of 1.6 and 
represented a 49.2% of patients with bacterial infection (n=317). In 
the other units, 199 isolates of Acinetobacter were collected, 
representing 3.7% of all isolates (n=5378) and 5.23% of Gram-
negative rods (n=3800) obtained in these units. These isolates were 
obtained from 137 infected patients. Among these patients, 69.3% 
were male, so a sex ratio equal to 2.3 and represented a rate of 
4.2% of whole patients with bacterial infection (n=3248). The 
difference in the prevalence of Acinetobacter related-infections 





Figure 1 shows the overall sensitivity patterns of clinical isolates 
of Acinetobacter sp with the resistance rate to colistin of 1.7%. The 
resistance rates difference between the ICUs and the other units 
was statistically significant (p< 0.05) except for colistin, tetracycline 
and rifampicin (Table 2). The resistance´s phenotypes to beta-
lactams have been dominated by the carbapenemase or alteration 
of porins (63.1%). The MDR´s percentage was 77.5% for the 
all Acinetobacter clinical isolates according to the used criteria. The 
MDR distribution rates in accordance with each kind of sample are 
shown in Table 3. The MDR´s rate was 92.6% in ICUs and 75.3% in 
other units. The MDR’s rate difference between the ICUs and the 





The present study shows that the infection Acinetobacter 
’s prevalence in HMIMV is high with higher rates in ICUs compared 
to other units (p <0.001). The isolation rate of Acinetobacter in the 
various samples was 6.94%.These results are higher compared to 
those from the study conducted by Mushtaq and al. (2013) [14] in 
Pakistan where the isolation rate of Acinetobacter species was 4.2% 
[11]. In an international study on the prevalence of infections in 
ICUs in 75 countries [10], the isolation rate of Acinetobacter (8.8%) 
was significantly lower than that of the ICUs (24.85 %) in our 
hospital. These clinical isolates represented 9.6% of all gram-
negative bacilli in the hospital and 31.5% in the ICUs. On the other 
hand, a study carried out in an Indian hospital reported a 
comparable rate as A. baumannii constituted 9.4% of all Gram-
negative rods throughout the hospital and 22.6% in the ICUs [20]. 
Our study shows that the frequency and resistance of 
Acinetobacter isolates are increasing in our hospital. Indeed, in 
2001, 147 clinical isolates of A. baumannii were isolated from all 
patients hospitalized in our institution and checked for bacterial 
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infection [22] against 441 clinical isolates in our study period; April 
1st, 2012 to April 1st, 2014. This high prevalence observed in our 
study is probably related to non-compliance with the 
recommendations for mastery the hospital environment [24], lack in 
hands hygiene and misuse of antibiotics [25]. Some studies have 
reported that this microorganism which has emerged worldwide as a 
pathogen causing serious infections in hospitalized patients has the 
ability to persist in the environment for a long period of time, 
colonize patients or healthy subjects and can develop into a true 
infection at any time [26]. Since hand transmission is a major factor 
in the spread of this pathogen [24], hand hygiene and disinfection 
of equipment/environment are the two most important factors to 
control and prevent the outbreak of an epidemic Acinetobacter [24]. 
 
In our study, 65.2% of affected patients were male. The 
predominance of male patients infected with Acinetobacter has been 
verified in other studies but the reason is not justified [2, 3, 5, 11]. 
The average age of patients in our study was 54 years (2-101 
years) with predominance of patients over 17 years; these results 
are similar to those of many authors [2, 3, 5, 11]. The old age of 
patients was recognized as an independent risk factor of the 
acquisition of A. baumannii infection [5]. Many authors have 
reported the predominance of Acinetobacter strains in broncho-
pulmonary samples [7, 20, 27]. In this study, the main isolation site 
of these clinical isolates was also broncho-pulmonary (44.67%) 
followed by blood cultures (14.51%). The Acinetobacter spp 
infections are generally involved in anatomical sites with a high fluid 
content manifested by pneumonia, bacteremia, urinary tract 
infection, meningitis and wound infection [1]. Several studies have 
shown that the high frequency of A. baumannii pneumonia is 
associated with mechanical ventilation [3,28] resulting in extended 
stays in ICUs, the rapid development of resistance to commonly 
used antibiotics and a high mortality ranging from 45.6 to 84.3% 
according to the authors [3,28]. The majority of clinical isolates in 
this study were essentially of A. baumannii (87.1%). The research 
by Chuang and al. (2011) demonstrated that among Acinetobacter 
species, A. baumannii is the main cause of Acinetobacter infections 
with the antibiotic resistance rate being very high causing more 
serious infections than other species of Acinetobacter [29]. In 
general, the Acinetobacter isolates are known for their resistance to 
various antibiotics despite their weak virulence limiting the control 
and infections treatment due to these microorganisms [1-5]. Our 
study shows that the rate of antibiotic resistance in our hospital is 
generally high and variable. Several authors have confirmed the 
high prevalence of these infections associated with high resistance 
in ICUs [7,17,20,30]. The high proportion and the high resistance of 
these microorganisms in ICUs are related to the existence of 
numerous risk factors associated with Acinetobacter infection such 
as immunocompromised persons, longer duration of stay in 
hospitals, invasive devices use on patients, the broad spectrum 
antibiotics therapy, possible and frequent contaminations and cross 
transmission of this bacteria through environmental reservoirs and 
hands of healthcare workers [3,24]. For the beta-lactam antibiotics 
which are a large family playing an important role in antimicrobial 
treatment [31], the high resistance of Acinetobacter clinical isolates 
to this class of antibiotics (ceftazidime, cefepime, imipenem and 
piperacillin / tazobactam) has been described in the literature [31]. 
In our study, the resistance rate against tested beta-lactam 
antibiotics ranged from 76% to 89% throughout the hospital, from 
87 to 98% in the ICUs and 59-75% in the other units. This rate is 
comparable to that observed in Asia, where it ranged from 56 to 
94% [14, 20, 27, 32]. In a Libyan study, the resistance was of 62.3 
to 98.8% throughout the studied hospital, 71.6-100% in the ICUs 
and from 42.6 to 96.2% in the other units [31]. The resistance to 
ceftazidime and cefepime was 86%. In the ICUs, the resistance rate 
to ceftazidime was 95.8% and 72.2% in the other units. This rate is 
higher than that obtained in the United States and South Africa in a 
similar study where the resistance to ceftazidime was 52.1% and 
68.4% respectively [8,21]. It ranges from 60 to 92.1% in studies in 
Asia [14, 20, 27, 32]. 
 
Carbapenems (imipenem, meropenem) remain one of the most 
important therapeutic options for these infections despite the fact 
that carbapenem-resistant strains are increasing [25]. In our study, 
the resistance to imipenem was 76.19% throughout the hospital 
and 87.7% in the ICUs. This rate is lower than that noted in India, 
where the resistance to imipenem reached 89.6 % [20] and higher 
than those of previous studies in Morocco: 23.6% [22] in 2001, 
42.6% in 2005 [7] and those obtained in the United States and 
Saudi Arabia, where the resistance to imipenem was 44.7% and 
61.3% respectively [18,21]. Carbapenem resistance in A. 
baumannii is often due to the expression of OXA carbapenemase 
types, Metallo-beta-lactamases (MBL) carbapenemase and the 
impermeability associated with mutations altering the expression of 
porins and efflux pumps [3,30]. In this study, most of 
the Acinetobacter strains showed the phenotype having resistance 
to beta-lactam antibiotics associated with the expression of 
carbapenemase or alteration of porins (63, 1%). These results are 
not in accordance with those found in another study conducted in 
the same hospital where the penicillinase phenotype and high level 
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cephalosporinase production were predominant with a rate of 33% 
[22]. In a Tunisian study, the majority of A. baumannii trains had 
the penicillinase phenotype in 26.3% of cases [19]. This emphasizes 
the alarming increase in resistance to imipenem and the expression 
of carbapenemase often related to the misuse of this antibiotic class 
in the clinical departments of our hospital. For the aminoglycosides, 
netilmicin was the most effective with a resistance rate of 33.07% 
against 43.03% for tobramycin and 52.28% for amikacin. Our data 
are different and lower than those obtained by Jaggi and al. (2012) 
in India; where resistance to tobramycin, gentamicin, netilmicin and 
amikacin were 80.0, 85.8, 90.3 and 90.3% respectively [19]. The 
aminoglycosides resistance in Acinetobacter spp. involves the 
production of aminoglycosides modifying enzymes and genes 
encoding these enzymes can be acquired through plasmids, 
transposons or integrons [3, 20]. The rate of resistance to 
ciprofloxacin observed in our study (87.7%). This rate is comparable 
to that reported in the literature which varies from 28.8 to 91.6% 
[8,17-20]. The prescription of this drug in the treatment 
of Acinetobacter infections is rare because of the high resistance to 
this antibiotic in our institution. Rifampicin was very effective (but 
less than colistin) with a resistance rate of 32.11%, but the use of 
this drug in the treatment of Acinetobacter infections is limited 
because Morocco is a country of endemic tuberculosis. Colistin was 
the most active antibiotic against Acinetobacter. In this study, the 
resistance to colistin was 1.7%. 
 
Some studies have reported that no clinical isolate 
of Acinetobacter was resistant to colistin [13, 22] but the resistance 
to colistin has been described in India, South Africa and Korea 
[20, 33]. Several authors confirm that colistin remains the only 
option for empirical treatment of serious Acinetobacter infections in 
cases where this bacterium is strongly suspected to be resistant to 
other antibiotics [12, 19]. The mechanism of resistance to this 
antibiotic is rare and may be explained by the loss of 
lipopolysaccharide and/or deployment of a system of two-
component regulatory PmrAB [34, 35]. Synergy between colistin 
and rifampicin or anti-Pseudomonas carbapenem is described in 
some studies [25]. There are no specific recommendations 
regarding the combination of antibiotics for the treatment of these 
serious infections due to the lack of prospective comparative clinical 
trials with a control group [25]. The combination therapy used in 
ICUs departments of our hospital includes colistin associated with 
imipenem or rifampicin. The resistance to ceftazidime and imipenem 
was 86.03% and 76.19% respectively in this study versus 63.3% 
and 23.3% respectively in 2001. The resistance to colistin increased 
slightly in our study by 1.7% against 0 % in 2001 [22]. This 
increase in resistance to these antibiotics can be explained by the 
uncontrolled growth of their consumption in our hospital. However 
there was a decrease in resistance to tobramycin and 
sulfamethoxazole / trimethoprim: 70.8% and 83.1% respectively in 
2001 [22] as against 43.03% and 78.96% respectively in our study, 
probably linked to general down use of these categories of 
antibiotics in our hospital. 
 
The current study demonstrated that the percentage of 
MDR Acinetobacter was 77.4% throughout the hospital and extents 
92.6% in ICUs and 75.3% in the other units with a rate difference 
that was statistically significant between the ICUs and the other 
units (p <0.001). Depending on the nature of each sampling site, 
the highest MDR Acinetobacter percentage (94.1%) was observed in 
vascular catheters followed by broncho-pulmonary samples (89.4%) 
and the lowest MDR Acinetobacter percentage (52.83%) was found 
in urine samples. These results are comparable to conclusions of a 
Lebanese study where rates of MDR Acinetobacter varied between 
73.4% and 77.7% [16] but higher than and non-similar to the 
findings observed in the United States (54%) with higher frequency 






In this study, we showed that, in our hospital, the frequency and 
rates of MDR Acinetobacter infection are high and could pose a real 
problem and a management impasse. A strict control of the hospital 
environment, hand hygiene and optimizing the use of antibiotics is 
recommended in order to reduce the MDR frequency. 
 
What is known about this topic 
 Acinetobacter is a non-fermenting Gram negative 
coccobacillus with a high capacity to colonize the human 
body and the environmental reservoirs and it is associated 
with a high morbidity and a high mortality rate especially 
in immunocompromised patients. 
 Acinetobacter is an opportunistic pathogen known for its 
intrinsic resistance to antibiotics and greater ability to 
rapidly acquire resistance genes. 
 It generally has resistance to several antibiotics and 
MDR Acinetobacter baumannii is becoming a global threat 
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with a therapeutic impasse increasingly described in 
literature. 
 
What this study adds 
 This is the first study which shows the prevalence rate of 
infections and antibiotic resistance level in clinical isolates 
of Acinetobacter by comparing data from the intensive 
care units versus other units in our hospital and in our 
region. 
 This study shows that the frequency and resistance 
of Acinetobacter isolates are increasing in our hospital. 
 This is the first Moroccan study that reports the rate of 
MDR Acinetobacter . The infection Acinetobacter’s 
prevalence and the MDR Acinetobacter rate were statically 
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Table 1: Repartition of clinical isolates of Acinetobacter by units and sampling site 
Samples nature ICUs (%) Other units (%) Total (%) 
Bronchopulmonary 64,8 14 44,67 
Blood cultures 15,7 12,7 14,51 
Deep pus 5 23,6 12,47 
Urine + Urinary catheters 6,6 22,3 12,02 
Superficial pus 3,3 19,7 9,07 
Vascular catheters 2,1 4,5 3,85 
Tissues and biopsies 1,7 1,3 1,81 
Fluids of puncture 0,8 1,9 1,6 
Table 2: Comparison of Acinetobacter  resistance rates in ICUs versus other units 
Antibiotics 
Resistance rates (in %) 
p Total (n=441) ICUs (n=242) other units 
(n=199) 
Ticarcillin 89,00 98,3 75,46 p< 0.001 
Piperacillin 87,56 97,85 72,84 p< 0.001 
Ticarcilline/ clavulanic acide 87,41 95,7 76,23 p< 0.001 
Piperacillin/Tazobactam 79,15 90,7 61,15 p< 0.001 
Ceftazidime 86,03 95,8 72,12 p< 0.001 
Cefepime 86,17 94,66 73,76 p< 0.001 
Imipenem 76,19 87,7 59,51 p< 0.001 
Tobramycin 43,03 44 30,91 p< 0.001 
Amikacin 52,28 59,3 42,33 p=0,027 
Netilmicin 33,07 38,4 25,16 p=0,033 
Ciprofloxacin 87,78 96,6 75,00 p< 0.001 
Sulfaméthoxazole/Trimetoprim 78,96 87,3 66,88 p< 0.001 
Colistin 1,7 1,68 1,79 p=0,869 
Tetracycline 90,89 93,53 87,12 p=0,146 
Rifampicin 32,11 34,3 28,97 p=0,403 
MDR rate 77,5 92,6 75,3 p< 0.001 
















Figure 1: Susceptibility pattern of clinical isolates of Acinetobacter 
 
 
Table 3: Proportion of the MDR Acinetobacter  clinical isolates by sampling site 
Sampling sites Number of isolates % MDR 
bronchopulmonary 197 89,43 
blood culture 64 70,3 
deep pus 55 70,9 
superficial pus 40 67,5 
catheters 17 94,1 
urine 53 52,83 
Fluids of puncture 7 71,42 
tissue 8 75 
total 441 77,5 
